Biotech: Page
-
Emerging biotech
Roche, Dualitas team up to find bispecific drugs for immune diseases
Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.
By Gwendolyn Wu • Sept. 17, 2026 -
Novartis to pay $125M for blood-brain barrier crossing platform
Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.
By Delilah Alvarado • Sept. 16, 2026 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Startup launches
Sling banks $123M for an experimental thyroid eye disease pill
A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.
By Gwendolyn Wu • Sept. 16, 2026 -
Skyhawk racks up more support for Huntington’s drug
The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.
By Jacob Bell • Sept. 16, 2026 -
News roundup
FDA clears first generic radioligand drug; Sionna turns to layoffs
A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.
By BioPharma Dive staff • Sept. 15, 2026 -
This week in charts
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin Group.
By Jacob Bell • Sept. 11, 2026 -
News roundup
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.
By BioPharma Dive staff • Sept. 11, 2026 -
Tyra disappoints investors with bladder cancer data
Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.
By Jonathan Gardner • Sept. 9, 2026 -
Startup launches
Kura spins diabetes work into a Lilly-backed biotech startup
Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.
By Gwendolyn Wu • Sept. 9, 2026 -
Startup launches
A new immuno-oncology play raises $225M for a next-generation drug
Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.
By Gwendolyn Wu • Sept. 9, 2026 -
News roundup
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.
By Delilah Alvarado • Sept. 8, 2026 -
Obesity drugs
Moonwalk reloads with $70M and new RNAi prospects for obesity
The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.
By Gwendolyn Wu • Sept. 8, 2026 -
BrainChild hauls in $116M to make cell therapies for childhood brain cancers
Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.
By Gwendolyn Wu • Sept. 8, 2026 -
This week in charts
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.
By Gwendolyn Wu • Sept. 4, 2026 -
News roundup
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
By BioPharma Dive staff • Sept. 4, 2026 -
Emerging biotech
An AI drug specialist zeroes in on rare forms of obesity
Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed medicine Imcivree.
By Gwendolyn Wu • Sept. 3, 2026 -
China competition
GSK wagers up to $1.3B on a different kind of cancer drug
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.
By Delilah Alvarado • Sept. 3, 2026 -
Akeso, Summit cancer drug confirms lung cancer survival benefit
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
By Jonathan Gardner • Sept. 3, 2026 -
News roundup
Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.
By BioPharma Dive staff • Sept. 2, 2026 -
Sponsored by Verily Health
The next frontier: Advancing foundation models with multimodal data
What's possible when AI models can learn from additional health data modalities to create a more complete understanding of human health?
Aug. 31, 2026 -
News roundup
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
By BioPharma Dive staff • Aug. 28, 2026 -
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.
By Jonathan Gardner • Aug. 28, 2026 -
This week in charts
This week in charts: Biotech’s rebound is undeniable
Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.
By Jacob Bell • Aug. 28, 2026 -
FDA green lights Priovant drug for rare skin disease
Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.
By Gwendolyn Wu • Updated Aug. 28, 2026 -
Q&A // Emerging biotech
Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company.
Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious about steering clear of road bumps that slow biotechs.
By Jacob Bell • Aug. 27, 2026